Latest Juno Therapeutics Inc. Stories
SEATTLE, Dec. 1, 2014 /PRNewswire/ -- Juno Therapeutics today announced the appointment of Jeffrey Bluestone, PhD, as scientific advisor.
SEATTLE, Nov. 18, 2014 /PRNewswire-USNewswire/ -- Juno Therapeutics, Inc.
SEATTLE, Nov. 17, 2014 /PRNewswire-USNewswire/ -- Juno Therapeutics, Inc. today announced that it has filed a registration statement on Form S-1 with the U.S.
Total Investment Tops $300M in Less Than 12 Months SEATTLE, Aug.
Juno CEO Hans Bishop to Address JP Morgan's 32nd Annual Healthcare Conference SEATTLE, Jan.